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OBJECTIVE—Diabetic postinfarction patients are at increased mortality risk compared with
nondiabetic postinfarction patients. In a substantial number of these patients, diabetic cardiac
neuropathy already preexists at the time of the infarction. In the current study we investigated if
markers of autonomic dysfunction can further discriminate diabetic postinfarction patients into
low- and high-risk groups.
RESEARCH DESIGN AND METHODS—We prospectively enrolled 481 patients with
type 2 diabetes who survived acute myocardial infarction (MI), were aged #80 years, and
presented in sinus rhythm. Primary end point was total mortality at 5 years of follow-up. Severe
autonomic failure (SAF) was deﬁned as coincidence of abnormal autonomic reﬂex function
(assessed by means of heart rate turbulence) and of abnormal autonomic tonic activity (assessed
by means of deceleration capacity of heart rate). Multivariable risk analyses considered SAF and
standard risk predictors including history of previous MI, arrhythmia on Holter monitoring,
insulin treatment, and impaired left ventricular ejection fraction (LVEF) #30%.
RESULTS—During follow-up, 83 of the 481 patients (17.3%) died. Of these, 24 deaths were
sudden cardiac deaths and 21 nonsudden cardiac deaths. SAF identiﬁed a high-risk group of 58
patients with a 5-year mortality rate of 64.0% at a sensitivity level of 38.0%. Multivariately, SAF
was the strongest predictor of mortality (hazard ratio 4.9 [95%CI 2.4–9.9]), followed by age$65
years (3.4 [1.9–5.8]), and LVEF #30% (2.6 [1.5–4.4]).
CONCLUSIONS—Combined abnormalities of autonomic reﬂex function and autonomic
tonic activity identiﬁes diabetic postinfarction patients with very poor prognoses.
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D iabetes remains one of the leadingcauses of death in the industrializedworld despite considerable recent
attention. Diabetic patients with histories
of myocardial infarctions (MIs) have par-
ticularly poor prognoses (1). A substantial
number of deaths in these patients occur
suddenly and might thus be preventable
by prophylactic implantation of implant-
able cardioverter deﬁbrillators (ICDs). As
implanting ICDs in all diabetic post-MI
patients would not be cost-effective, fur-
ther risk stratiﬁcation of this patient pop-
ulation is necessary. At present, left
ventricular ejection fraction (LVEF) is
the gold standard tool for post-MI risk
stratiﬁcation (2). However it is neither
speciﬁc nor sensitive. This problem is
not related to diabetic patients because
risk stratiﬁcation in the general post-
infarction population suffers from the
same shortcoming. Therefore, additional
risk stratiﬁcation tools, including the as-
sessment of autonomic dysfunction, have
been proposed for the general postinfarc-
tion population.
In diabetic postinfarction patients,
autonomic function can be affected by
both the infarction, including its compli-
cations, and the preexisting cardiac auto-
nomic neuropathy (2–4). This might
compromise risk-predictive value of the
autonomic markers. Therefore, this study
was undertaken to investigate whether
markers of autonomic dysfunction are of
prognostic value in the clinical setting of
acute MI complicated by a preexisting di-
abetic cardiac neuropathy.
Heart rate turbulence (HRT) (5) and
deceleration capacity (DC) (6) are Holter-
based techniques that capture different
aspects of autonomic control. HRT quan-
tiﬁes an autonomic reﬂex, namely the
heart rate response to the transient fall
of arterial pressure caused by ventricular
premature complexes (VPCs). DC is sup-
posed to be representative of tonic vagal
activity. Coincidence of abnormal HRT
and DC are suggestive of severe auto-
nomic failure (SAF). In unselected post-
MI patients, SAF indicated high risk of
subsequent death (7). In the current
study of diabetic post-MI patients, we
tested the association of SAF with 5-year
mortality and the improvement of risk
prediction by adding SAF to the LVEF
gold standard.
RESEARCH DESIGN AND
METHODS—Between January 1996
and March 2005, survivors of acute MI
(,4 weeks) were enrolled at two large
university hospitals, the German Heart
Centre and the Klinikum Rechts der
Isar, both located in Munich, Germany.
Patients were included if they suffered
from type 2 diabetes, were aged #80
years, presented in sinus rhythm, and
did not meet the criteria for secondary
ICD therapy (i.e., had cardiac arrest or
documented sustained ventricular tachy-
cardia). Type 2 diabetes was considered
present if a patient was already diagnosed
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and was receiving treatment (diet, tablets,
or insulin) or if fasting blood glucose
concentration repeatedly exceeded 11
mmol/L. MI was diagnosed in the pres-
ence of at least two of the following three
ﬁndings: 1) chest pain for $20 min,
2) creatine kinase-MB above the double
upper normal limit of our laboratory,
and 3) ST-segment elevation of $0.1 mV
in two or more limb leads or $0.2 mV in
two or more contiguous precordial leads.
Patients were followed up for a median of
3.9 (interquartile range 2.1–6.2) years.
The Ethics Committee of Technische Uni-
versität München approved the collection
of data and analysis of Holter recordings.
Because the study data were noninvasive
and obtained as a part of standard clinical
management, the local ethics committee
did not require signed informed consent.
However, oral informed consent was ob-
tained in all cases.
Assessment of reﬂex and tonic
autonomic markers
In all patients, 24-h Holter electrocardio-
grams were recorded within 2 weeks of
enrollment. All recordings were routinely
processed using standard commercial
equipment (Oxford Excel Holter system,
Oxford Instruments; Pathﬁnder 700,
Reynolds Medical; and Mortara Holter
system, Mortara Instrument) to obtain
the sequence of individual R-R intervals
together with the distinction of sinus
rhythm beats and ventricular premature
complexes.
HRT is composed of an initial heart
rate acceleration followed by a subse-
quent heart rate deceleration (8). The
two phases of HRT are quantiﬁed by
two numerical descriptors, turbulence
onset (TO) and turbulence slope (TS).
HRT was considered abnormal if both
TO and TS were abnormal (TO $0%
and TS #2.5 ms per heartbeat interval,
respectively) (8). DC was considered ab-
normal if #4.5 ms (6).
The association of HRT and DC with
autonomic abnormalities was previously
reported (6,9).
Deﬁnition of categories of
autonomic dysfunction
Normal autonomic function (NAF) was
assumed if both HRT and DC were
normal. Mild autonomic failure (MAF)
was assumed if only one of HRT and DC
was normal while the other was abnor-
mal. Severe autonomic failure (SAF) was
assumed if both HRT and DC were
abnormal.
Other risk predictors
Other evaluated risk predictors included
age, sex, history of previous MI, standard
deviation of normal-to-normal heartbeat
intervals (SDNN) (10), mean heart rate,
arrhythmias during Holter monitoring,
insulin dependency, and LVEF. LVEF
was assessed by left ventricular angiogra-
phy or biplane echocardiography. In the
latter case, a phased-array system (Sonos
5500, Hewlett Packard) was used.
Variables were dichotomized at pre-
deﬁned cutoff values based on previous
publications: LVEF #30%, age $65
years, SDNN #70 ms, mean heart rate
$75 bpm, single VPCs $10 per h, and
presence or absence of nonsustained ven-
tricular tachycardia (nsVT) (11). The lat-
ter two parameters deﬁned arrhythmia
categories: negative (,10 VPCs per h
and absence of nsVT) and positive ($10
VPCs per h or presence of nsVT in 24 h).
Renal impairment was deﬁned as the es-
timated glomerular ﬁltration rate (eGFR)
#60 ml/min/1.73 m2 (12).
Study end points
If a patient died during follow-up, the
reason for death was veriﬁed from hospi-
tal and autopsy records and from either
the primary physician or those witnessing
the death. An independent end point
committee adjudicated the mode of death.
Deaths were categorized as cardiac and
noncardiac. Cardiac deaths were further
categorized as sudden and nonsudden.
Cardiac death was deﬁned as sudden if
it was a witnessed death occurring within
60 min of the onset of new symptoms
unless 1) there was an obvious noncar-
diac cause, or 2) if it was an unwitnessed
death in the absence of preexisting pro-
gressive circulatory failure or other causes
of death, or 3) if it was a death during
attempted resuscitation. The primary
end point of the study was all-cause mor-
tality within the ﬁrst 5 years of follow-up;
secondary end points were cardiac and
sudden cardiac death also within the ﬁrst
5 years of follow-up.
Data analysis and statistics
We investigated both the association of
the autonomic dysfunction categories
with outcome and the improvement of
risk prediction by adding these categories
to the current LVEF-based standard of
risk prediction. Continuous variables are
presented as median and interquartile
range; qualitative data are expressed as
percentages. Mortality rates were esti-
mated by the Kaplan-Meier method (13)
and compared by two-sided log-rank test.
Secondary end points (cardiac death and
sudden death) were analyzed with com-
peting risk models (14) using R and com-
pared with the procedure proposed by
Gray (15). Multivariable analyses were
performed using a two-sided Cox propor-
tional hazards model with enter proce-
dure of all risk predictors considered
(Table 2). Hazard ratios (HRs) are pre-
sented with 95% CIs. The diagnostic prop-
erties of the different prognostic systems
are characterized by sensitivity, speciﬁcity,
and predictive values calculated to reﬂect
the number of expected deaths in case
of censored data (16). The change in the
difference in the predicted probabilities
of the outcome after introducing SAF
to LVEF was estimated by the integrated
discrimination index (IDI) (17), where a
better model is reﬂected by a greater dif-
ference in the predicted probabilities. Dif-
ferences were considered statistically
signiﬁcant if P , 0.05 (SPSS 18.0, SPSS
Inc.).
RESULTS—During the recruitment pe-
riod, 481 patients were enrolled. Table 1
shows the clinical characteristics of the
patients. The median of creatine kinase
maximum was 1,114 units/L. Median
LVEF was 51%. Percutaneous coronary
interventions were performed in 89% of
the patients. The adjuvant medication
consisted of aspirin in 99%, b-blockers
Table 1—Patients characteristics of the
study population
Characteristic n = 481
Age (years) 65 (57–72)
Female sex 137 (28)
Oral antidiabetic drugs 276 (57)
Insulin dependency 139 (29)
History of previous MI 75 (16)
CKmax (U/l) 1,114 (494–2,400)
Creatinine (mg/dL) 1.1 (0.9–1.3)
eGFR (ml/min/1.73 m2) 70 (55–88)
LVEF (%) 51 (42–59)
VPC (counts per h) 0.5 (0.1–3.6)
Nonsustained VT 39 (8)
Abnormal HRT 73 (15)
DC #4.5 ms 250 (52)
NAF 216 (45)
MAF 207 (43)
SAF 58 (12)
Data are median (interquartile range) or n (%).
CKmax, creatine kinase maximum; VT, ventricular
tachycardia; abnormal HRT, abnormality deﬁned as
coincidence of both abnormal turbulence onset and
abnormal turbulence slope.
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in 94%, ACE inhibitors in 94%, and statins
in 85%. Two hundred seventy-six (57.4%)
of the patients received oral antidiabetic
drugs; 139 (28.9%) of the patients were
treated with insulin. Follow-up informa-
tion was collected on all patients. Six pa-
tients were lost to follow-up. They were
censored at the date of last contact. During
the median follow-up of 3.9 years, 83
diabetic patients died; out of these, 21
deaths were classiﬁed as nonsudden car-
diac and 24 as sudden cardiac deaths.
Another 28 deaths were classiﬁed as non-
cardiac deaths, while the mode of death
could not be speciﬁed in 10 cases.
Association of autonomic
dysfunction with the primary
end point
Fifty-eight patients had SAF (12.1%), 207
patients hadMAF (43.0% [abnormal DC in
192 patients, abnormal HRT in 15 pa-
tients]), and216patients hadNAF (44.9%).
In univariable analysis, all risk factors
with the exception of sex were signiﬁ-
cantly associated with 5-year mortality;
SAF provided the highest HR of 11.2
(Table 2). In SAF patients, probability of
death within 5 years was 64.0% (positive
predictive value of 64% at 38% sensitivity
[Table 3]). In MAF and NAF patients, the
probabilities of death within 5 years were
22.6 and 8.9%, respectively (Fig. 1A).
In multivariable analysis, SAF pro-
vided the highest HR of 4.9 (95% CI
2.4–9.9, P , 0.0001 [Table 2]). Other
multivariately independent risk predic-
tors were age $65 years (3.4 [1.9–5.8],
P, 0.0001); LVEF#30% (2.6 [1.5–4.4],
P = 0.001), and history of previous MI
(1.7 [1.1–2.8], P = 0.028).
Association of autonomic
dysfunction with secondary
end points
SAF was also a statistically signiﬁcant pre-
dictor of cardiac death and sudden car-
diac death (Fig. 1B and C). Probability of
cardiac death within 5 years was 3.8% in
NAF patients. In MAF and SAF patients,
these numbers were 9.7 and 42.8%, re-
spectively. Probability of sudden death
within 5 years was 2.1, 5.9, and 19.5% in
NAF, MAF, and SAF patients, respectively.
Improvement of risk prediction
by SAF
If SAF was added to LVEF, a signiﬁcant
improvement in performance of the risk
stratiﬁcation model was observed (IDI,
0.022; P , 0.0001). In the large group
of patients with LVEF .30%, SAF
identiﬁed a patient subgroup of similar
size and mortality risk as patients with
depressed LVEF (Fig. 2).
LVEF#30% occurred in 38 patients.
Of these, 20 patients died during the
follow-up period. Another 63 patients
died despite having LVEF .30%. These
numbers translate to a positive predictive
value of 57% at a sensitivity level of 22%
(Table 3).
Risk prediction was more precise if
LVEF and SAF were used in combination.
Eighty-two patients fulﬁlled the criterion
“LVEF #30% or SAF.” Out of these, 41
patients died during the follow-up
period. Another 42 patients died despite
having neither LVEF #30% nor SAF.
These numbers translate to a positive pre-
dictive value of 58% at a sensitivity level of
48% (Table 3). The increase in sensitivity
by adding SAF to LVEF from 22 to 48%
was statistically signiﬁcant (P, 0.0001).
Comparable improvements of sensi-
tivity without compromising positive pre-
dictive accuracies were observed with
secondary end points (Table 3).
CONCLUSIONS—In our population
of diabetic post-MI patients, SAF was
strongly associated with 5-year mortality.
Table 2—Uni- and multivariable analyses for prediction of total mortality within
5 years of follow-up
Univariable analysis Multivarible analysis
HR (95% CI) P value HR (95% CI) P value
Age $65 years 3.6 (2.2–6.0) ,0.0001 3.4 (1.9–5.8) ,0.0001
Female sex 1.4 (0.9–2.2) 0.150 0.8 (0.5–1.3) 0.301
Previous MI 2.4 (1.5–3.9) ,0.0001 1.7 (1.1–2.8) 0.028
Arrhythmia 2.0 (1.3–3.2) 0.002 1.1 (0.7–1.8) 0.750
LVEF #30% 4.7 (2.8–7.8) ,0.0001 2.6 (1.5–4.4) 0.001
Insulin dependency 1.6 (1.0–2.5) 0.045 1.4 (0.9–2.3) 0.117
Mean heart rate $75 bpm 2.3 (1.4–3.5) ,0.0001 1.5 (0.9–2.5) 0.087
SDNN #70 ms 2.3 (1.5–3.6) ,0.0001 1.4 (0.9–2.3) 0.169
eGFR #60 ml/min/1.73 m2 2.1 (1.4–3.2) 0.001 1.2 (0.8–1.9) 0.347
MAF 2.7 (1.5–4.9) 0.001 1.5 (0.8–2.8) 0.237
SAF 11.2 (6.1–20.5) ,0.0001 4.9 (2.4–9.9) ,0.0001
Table 3—Mortality rates, sensitivities, and speciﬁcities for prediction of all-cause
mortality, cardiac mortality, and sudden cardiac death in high-risk groups
LVEF #30% SAF
LVEF #30%
or SAF
LVEF #30%
and SAF
n 38 58 82 14
Prediction of all-cause mortality at 5 years
All-cause deaths 20 31 41 10
Mortality rate (%) 57.2 64.0 58.2 76.2
Sensitivity (%) 21.7 38.0 47.7 10.6
Speciﬁcity (%) 95.7 94.6 90.9 99.1
PPV (%) 57.2 64.0 58.2 76.2
Prediction of cardiac mortality at 5 years
All-cause deaths 12 21 28 5
Mortality rate (%) 40.5 48.1 43.3 55.9
Sensitivity (%) 28.3 49.2 65.3 14.1
Speciﬁcity (%) 94.7 92.9 88.8 98.5
PPV (%) 40.5 48.1 43.3 55.9
Prediction of sudden cardiac mortality at 5 years
All-cause deaths 6 10 15 1
Mortality rate (%) 25.2 24.2 25.9 14.3
Sensitivity (%) 30.9 44.7 69.0 6.7
Speciﬁcity (%) 93.7 90.2 86.2 97.3
PPV (%) 25.0 24.2 25.9 14.3
PPV, positive predictive value.
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Twelve percent of all patients showed
signs of SAF and had a very poor prog-
nosis; two out of three of these patients
died within 5 years. SAF was also strongly
associated with cardiac death and sud-
den death. Surprisingly, almost half of the
population was in the NAF category with
no signs of autonomic failure. Their
5-year mortality rates were low at 8.9%
for death by any cause, 3.8% for cardiac
death, and 2.1% for sudden death.
The addition of SAF to the standard
risk model improved the risk prediction
in diabetic post-MI patients. Compared
with the LVEF #30% alone, the combi-
nation of SAF or LVEF #30% more than
doubled the sensitivity of all-cause mor-
tality prediction while practically preserv-
ing the positive predictive value.
In a diabetic post-MI patient, auto-
nomic function can be affected by se-
quelae of diabetes, by sequelae of MI, or
by a combination of both. Either pathol-
ogy, i.e., infarction and diabetes-related
autonomopathy, has been separately linked
to an increased mortality risk (18,19). A
substantial fraction of diabetic post-MI
patients presenting with SAF might suffer
from a combination of both. We hypothe-
size that in every individual there is auto-
nomic defense that has a “reserve” and
thus remains functional even if partially
damaged by different pathologies. When
different pathologies are present at the
same time, the reserve is exhausted and
the autonomic defense might be lost com-
pletely.
There are examples where coinci-
dence of different autonomopathies is
associated with poor outcome. Such ex-
amples include the combination of de-
pression and MI (20), the combination of
depression and end-stage renal disease
(21), or the combination of diabetes and
end-stage renal disease (22).
Our study has important clinical im-
plications. Patients with SAF should re-
ceive intensive cardiac therapy based on a
multifactorial approach including tight
ambulatory monitoring, regular screening
for progression of coronary artery disease,
optimum medical therapy of heart failure,
and ﬁnally prophylactic implantation of a
cardioverter deﬁbrillator.
In this context of note, diabetic post-
MI patients, who generally are sicker and
at higher risk of subsequent death than
nondiabetic patients, beneﬁted equally
well from ICD therapy (23). Our ﬁndings
also have important implications for the
majority of patients with NAF. Because
these patients are at very low risk for ad-
verse events, costly and potentially haz-
ardous therapies can be safely avoided.
Any novel risk marker has to be tested
against the accepted gold standard for
its additive predictive value. In postin-
farction risk assessment, LVEF is such a
gold standard at present. By adding SAF
to LVEF, risk prediction improved sig-
niﬁcantly. Importantly, in a subset of
patients without severely impaired LVEF,
SAF identiﬁed a substantial number of
patients with mortality risk similar to
patients with depressed LVEF. As a conse-
quence, a twofold increase in sensitivity
was gained without sacriﬁcing speciﬁcity.
Limitations of our study should also
be recognized. Because we have no in-
formation about autonomic status prior
to the infarction, we cannot make deﬁnite
statements about the relative contribu-
tions of diabetes-related and infarction-
related autonomic damage. Moreover, we
have no detailed information about gly-
cemic status, HbA1c, and changes of
antidiabetic therapy after hospital dis-
charge. We investigated diabetic survivors
of myocardial infarction; we therefore can-
not make statements about clinical use-
fulness of SAF in the general diabetic
population. We did not perform reﬂex
tests as suggested by Ewing et al. (24).
Figure 1—Cumulative rates of deaths, cardiac deaths, and sudden deaths in patients of the study population stratiﬁed according to the degree of
autonomic dysfunction (NAF,MAF, SAF). The numbers of patients of the individual groups involved in the analysis at 0, 1, 2, 3, 4, and 5 years are shown
below each graph; the order of the rows corresponds to the order of the mortality curves. *Test by log-rank statistics; **test according to Gray’s method.
Figure 2—Total mortality in patients with
LVEF#30%, LVEF.30% and SAF, and LVEF
.30% and MAF or NAF. The numbers of pa-
tients of the individual groups involved in the
analysis at 0, 1, 2, 3, 4, and 5 years are shown
below the graph; the order of the rows corre-
sponds to the order of the mortality curves. Tests
were done by log-rank statistics; pairwise com-
parisons: 1) LVEF .30% and MAF or NAF vs.
LVEF .30% and SAF, P , 0.001; 2) LVEF
.30% and MAF or NAF vs. LVEF #30%, P ,
0.001; 3) LVEF.30% and SAF vs. LVEF#30%,
P5 0.88.
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Thus, we are not able to compare their
usefulness with that of SAF. Our results
are limited to patients aged #80 years
and should not be extrapolated to older
patients. Finally, by its signal processing
nature, SAF assessment is limited to pa-
tients in primarily sinus rhythm.
In conclusion, our study shows that
among patients with diabetes and recent
MI, presence of SAF is associated with an
increased risk of total mortality.
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